Purple Biotech announced it will present data for its oncology candidate NT219, a first-in-class small molecule, dual-inhibitor of IRS 1/2 and STAT3, in two poster presentations at the American Association for Cancer Research, AACR, annual meeting which takes place April 5-11, 2024, in San Diego, California. “The growing body of clinical, biomarker, and preclinical data for NT219 demonstrate its potential not only in the lead indication of recurrent/metastatic squamous cell carcinoma of the head and neck, but also in other solid-tumor cancers. These publications at AACR 2024 are a result of the progress made last year both in clinical and preclinical work bringing out NT219’s attributes,” stated Gil Efron, Chief Executive Officer of Purple Biotech. “We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PPBT:
- Purple Biotech reports preclinical proof of concept for tribody platform tech
- Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
- Purple Biotech reports Q4 EPS (19c), consensus (19c)
- Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
- Purple Biotech presents data of Phase 1 study of NT219